1Revenue increased 14.2% to $133.9M from $117.3M, reflecting growth in orthobiologics sales volume as volumes rose despite potential demand risks.
2Gross profit rose 23.5% to $84.3M with margin expansion to 62.9%, due to favorable product mix and scale efficiencies outweighing higher excess and obsolete inventory charges offset by internal production transition.
3Operating income improved 160.3% to $7.3M profit from -$12.1M loss, primarily from reduced commission expense on revenue mix shift and lower compensation from headcount reduction.
4Net income turned positive at $5.0M versus -$16.4M loss, supported by the profitability swing and net income position driving changes in cash taxes.
5Operating cash flow generated $12.5M versus -$12.0M prior use, with free cash flow of $10.2M after $2.4M capex, reflecting improved working capital from operations.
6Capex declined to $2.4M from $4.1M, shifting focus to efficiency and inventory optimization rather than expansion.